SwitzerlandSwitzerland

Clariant to take over German Süd-Chemie AG for EUR2bn

18.02.2011

Muttenz/Munich – Swiss chemistry specialist Clariant AG had made a 2bn bid for Munich-based catalysis and adsorbents specialist Süd-Chemie aimed at taking over the controlling majority from two groups of stockholders. The transaction, which is based on definite agreements with One Equity Partners who hold 50.4% of Süd-Chemie’s shares and the family shareholders (46%), is still subject to clearance by competent merger control authorities. When the deal goes through, Clariant will bag more than 95% of the outstanding shares. Süd-Chemie has a strong R&D pipeline that addresses future needs of the chemistry industry. The company has developed a economically promising approach in advanced development stage to generate cellulosic ethanol from the world’s most common straw feeds – rice straw, corn stover and bagasse. The Sun Liquid process, which has been proven economically feasible at pilot scale, is ready to be tested in a demonstration plant later this year. The company aimed at licensing out the technology world-wide as entry point to plant-based C-2 chemistry building blocks for manufacture of bulk bioplastics such as polyethylene, polypropylene or polyvinyl chloride. As a global leader in process catalysis and adsorbents Süd-Chemie provides the missing link between chemical process engineering and biocatalysis. In 2010, the Munich-based company had a turnover of EUR1.225 billion and EBITDA of EUR 191 million. After the acquisition of Danish Danico by US chemistry giant DuPont, Süd-Chemie has become is the second strategic target involving a world-leading biotechnology product pipeline. The issue of new shares is subject to approval at the Clariant general meeting on March 31, 2011.

SwitzerlandSwitzerland

22.08.2011

Liestal – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published the results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly...

SwitzerlandSwitzerland

18.08.2011

Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the...

SwitzerlandSwitzerland

16.08.2011

Reinach – Evolva SA has got its hands on up to €30m of fresh capital. The Swiss specialist for synthetic biology announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA...

SwitzerlandSwitzerland

15.08.2011

Basel/Waltham - Expecting to be bought by Novartis, U.S. biopharmaceutical firm Proteon Therapeutics Inc. has delivered a new $15.2 million financing. The Swiss pharmaceutical company Novartis obtained exclusive option to acquire...

SwitzerlandSwitzerland

03.08.2011

Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and...

SwitzerlandSwitzerland

13.07.2011

A big financier of biotech deals could be back on track soon. Novartis is interested in further acquisitions, CEO Joe Jimenez said in an interview published by the "Aargauer Zeitung", a Switzerland- based newspaper.The drugmaker...

SwitzerlandSwitzerland

11.06.2011

Basel – Swiss crop group Syngenta plans to construct a new biotech research facility adjacent to its existing research campus at the Research Triangle Park in North Carolina (US). The US$71m investment is scheduled to begin in...

Displaying results 31 to 40 out of 276

< Previous 31-40 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/3/article/clariant-to-take-over-german-sued-chemie-ag-for-eur2bn.html

Whitepaper

Video

All videos

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.75%
  • DIAXONHIT (F)0.79 EUR14.49%
  • ACTIVE BIOTECH (S)12.35 SEK10.27%

FLOP

  • ZELTIA (E)3.69 EUR-8.44%
  • SWEDISH ORPHAN BIOVITRUM (S)13.05 USD-6.12%
  • ALMIRALL (E)17.75 EUR-5.84%

TOP

  • DBV TECHNOLOGIES (F)79.24 EUR50.2%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.8%
  • DIAXONHIT (F)0.79 EUR43.6%

FLOP

  • BIOTEST (D)25.52 EUR-63.3%
  • BIOTECH PHARMACON (N)9.45 NOK-46.0%
  • EVOCUTIS (UK)0.17 GBP-22.7%

TOP

  • ADOCIA (F)86.78 EUR577.4%
  • FORMYCON (D)28.40 EUR323.2%
  • DBV TECHNOLOGIES (F)79.24 EUR317.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.10 SEK-70.6%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 02.08.2015

Current issue

All issues